Insmed Incorporated (NASDAQ:INSM) Given Consensus Recommendation of "Buy" by Analysts

Insmed Incorporated (NASDAQ:INSM - Get Free Report) has received an average rating of "Buy" from the sixteen ratings firms that are covering the firm, MarketBeat reports. Sixteen research analysts have rated the stock with a buy recommendation. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $94.00.

INSM has been the topic of several recent analyst reports. JPMorgan Chase & Co. lifted their price target on shares of Insmed from $83.00 to $92.00 and gave the company an "overweight" rating in a report on Friday, February 7th. HC Wainwright reaffirmed a "buy" rating and set a $90.00 target price on shares of Insmed in a research note on Friday, February 21st. UBS Group increased their price target on shares of Insmed from $105.00 to $110.00 and gave the stock a "buy" rating in a research note on Thursday, March 6th. Truist Financial lifted their price objective on Insmed from $105.00 to $108.00 and gave the company a "buy" rating in a research report on Friday, February 21st. Finally, Stifel Nicolaus decreased their target price on Insmed from $97.00 to $96.00 and set a "buy" rating for the company in a research report on Friday, February 21st.

Insider Activity at Insmed

In other Insmed news, CEO William Lewis sold 18,750 shares of the business's stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $69.84, for a total transaction of $1,309,500.00. Following the completion of the sale, the chief executive officer now directly owns 384,960 shares in the company, valued at approximately $26,885,606.40. The trade was a 4.64 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Martina M.D. Flammer sold 3,344 shares of the firm's stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $65.91, for a total value of $220,403.04. Following the completion of the transaction, the insider now owns 102,766 shares in the company, valued at approximately $6,773,307.06. This trade represents a 3.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 550,957 shares of company stock valued at $42,992,528. 4.60% of the stock is owned by corporate insiders.

Remove Ads

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in shares of Insmed by 6.3% in the fourth quarter. Vanguard Group Inc. now owns 18,218,973 shares of the biopharmaceutical company's stock worth $1,257,838,000 after buying an additional 1,075,796 shares during the last quarter. Darwin Global Management Ltd. lifted its position in Insmed by 23.5% during the fourth quarter. Darwin Global Management Ltd. now owns 12,960,538 shares of the biopharmaceutical company's stock valued at $894,796,000 after purchasing an additional 2,463,261 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of Insmed by 1.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 12,704,410 shares of the biopharmaceutical company's stock valued at $877,113,000 after acquiring an additional 123,429 shares during the period. Capital International Investors grew its stake in shares of Insmed by 9.1% during the 4th quarter. Capital International Investors now owns 7,116,997 shares of the biopharmaceutical company's stock valued at $491,357,000 after acquiring an additional 593,206 shares during the period. Finally, Geode Capital Management LLC increased its holdings in Insmed by 7.2% in the 4th quarter. Geode Capital Management LLC now owns 4,087,143 shares of the biopharmaceutical company's stock worth $282,243,000 after acquiring an additional 273,759 shares in the last quarter.

Insmed Trading Down 2.5 %

Shares of NASDAQ:INSM traded down $1.96 during midday trading on Friday, hitting $76.58. 765,160 shares of the stock traded hands, compared to its average volume of 1,839,203. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. The stock has a market capitalization of $13.86 billion, a PE ratio of -13.70 and a beta of 1.28. Insmed has a one year low of $21.92 and a one year high of $84.91. The business's 50 day moving average is $77.84 and its two-hundred day moving average is $73.89.

Insmed (NASDAQ:INSM - Get Free Report) last released its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.15). The business had revenue of $104.44 million for the quarter, compared to the consensus estimate of $102.31 million. Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. As a group, research analysts forecast that Insmed will post -4.56 earnings per share for the current year.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.